Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE: Ebola Vaccine Evaluation in Sierra Leone
NCT02378753Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Laboratory-confirmed Ebola (Study Diagnostics) and Number of Participants With Occurrence of Serious Adverse Events at 6 months. Started Apr 2015; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02378753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378753.